TELADOC HEALTH INC (TDOC) Stock Fundamental Analysis
USA - NYSE:TDOC - US87918A1051 - Common Stock
7.47 USD
-0.09 (-1.19%)
7.41 USD
-0.06 (-0.8%)
TDOC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 35 industry peers in the Health Care Technology industry. TDOC may be in some trouble as it scores bad on both profitability and health. TDOC is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year TDOC has reported negative net income.
In the past year TDOC had a positive cash flow from operations.
In the past 5 years TDOC always reported negative net income.
Of the past 5 years TDOC 4 years had a positive operating cash flow.
1.2 Ratios
TDOC's Return On Assets of -7.77% is fine compared to the rest of the industry. TDOC outperforms 62.86% of its industry peers.
Looking at the Return On Equity, with a value of -16.06%, TDOC is in the better half of the industry, outperforming 62.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.77% | ||
| ROE | -16.06% | ||
| ROIC | N/A |
ROA(3y)-115.95%
ROA(5y)-70.6%
ROE(3y)-222.82%
ROE(5y)-134.84%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 69.80%, TDOC is in the better half of the industry, outperforming 74.29% of the companies in the same industry.
In the last couple of years the Gross Margin of TDOC has remained more or less at the same level.
TDOC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.8% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.33%
GM growth 5Y1.2%
2. Health
2.1 Basic Checks
TDOC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TDOC has more shares outstanding
TDOC has more shares outstanding than it did 5 years ago.
The debt/assets ratio for TDOC is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -6.49, we must say that TDOC is in the distress zone and has some risk of bankruptcy.
TDOC has a Altman-Z score of -6.49. This is amonst the worse of the industry: TDOC underperforms 82.86% of its industry peers.
TDOC has a debt to FCF ratio of 7.09. This is a slightly negative value and a sign of low solvency as TDOC would need 7.09 years to pay back of all of its debts.
With a Debt to FCF ratio value of 7.09, TDOC perfoms like the industry average, outperforming 57.14% of the companies in the same industry.
TDOC has a Debt/Equity ratio of 0.71. This is a neutral value indicating TDOC is somewhat dependend on debt financing.
The Debt to Equity ratio of TDOC (0.71) is worse than 71.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | 7.09 | ||
| Altman-Z | -6.49 |
ROIC/WACCN/A
WACC7.74%
2.3 Liquidity
TDOC has a Current Ratio of 2.70. This indicates that TDOC is financially healthy and has no problem in meeting its short term obligations.
TDOC has a Current ratio (2.70) which is in line with its industry peers.
TDOC has a Quick Ratio of 2.60. This indicates that TDOC is financially healthy and has no problem in meeting its short term obligations.
TDOC has a Quick ratio (2.60) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.7 | ||
| Quick Ratio | 2.6 |
3. Growth
3.1 Past
The earnings per share for TDOC have decreased strongly by -13.27% in the last year.
The Revenue has decreased by -2.37% in the past year.
TDOC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 35.95% yearly.
EPS 1Y (TTM)-13.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.37%
Revenue 1Y (TTM)-2.37%
Revenue growth 3Y8.13%
Revenue growth 5Y35.95%
Sales Q2Q%-2.2%
3.2 Future
The Earnings Per Share is expected to grow by 6.70% on average over the next years.
The Revenue is expected to grow by 1.86% on average over the next years.
EPS Next Y4.23%
EPS Next 2Y17.66%
EPS Next 3Y12.29%
EPS Next 5Y6.7%
Revenue Next Year-1.79%
Revenue Next 2Y-0.31%
Revenue Next 3Y0.41%
Revenue Next 5Y1.86%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
TDOC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TDOC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
TDOC's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. TDOC is cheaper than 91.43% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, TDOC is valued cheaply inside the industry as 94.29% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.42 | ||
| EV/EBITDA | 8.81 |
4.3 Compensation for Growth
A more expensive valuation may be justified as TDOC's earnings are expected to grow with 12.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.66%
EPS Next 3Y12.29%
5. Dividend
5.1 Amount
TDOC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.47
-0.09 (-1.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners75.05%
Inst Owner Change1.36%
Ins Owners0.62%
Ins Owner Change6.12%
Market Cap1.32B
Revenue(TTM)2.53B
Net Income(TTM)-223.59M
Analysts68.13
Price Target9.33 (24.9%)
Short Float %14.27%
Short Ratio3.64
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.74%
Min EPS beat(2)-3.18%
Max EPS beat(2)28.67%
EPS beat(4)1
Avg EPS beat(4)-10.77%
Min EPS beat(4)-54.19%
Max EPS beat(4)28.67%
EPS beat(8)4
Avg EPS beat(8)3.56%
EPS beat(12)7
Avg EPS beat(12)-763.36%
EPS beat(16)10
Avg EPS beat(16)-740.69%
Revenue beat(2)0
Avg Revenue beat(2)-1.19%
Min Revenue beat(2)-1.88%
Max Revenue beat(2)-0.51%
Revenue beat(4)0
Avg Revenue beat(4)-1.14%
Min Revenue beat(4)-1.88%
Max Revenue beat(4)-0.35%
Revenue beat(8)0
Avg Revenue beat(8)-1.53%
Revenue beat(12)0
Avg Revenue beat(12)-1.49%
Revenue beat(16)0
Avg Revenue beat(16)-1.45%
PT rev (1m)1.39%
PT rev (3m)1.39%
EPS NQ rev (1m)-5.43%
EPS NQ rev (3m)-2.85%
EPS NY rev (1m)-3.91%
EPS NY rev (3m)-3.8%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)-0.05%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)0.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.52 | ||
| P/FCF | 9.42 | ||
| P/OCF | 4.51 | ||
| P/B | 0.95 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.81 |
EPS(TTM)-1.28
EYN/A
EPS(NY)-0.76
Fwd EYN/A
FCF(TTM)0.79
FCFY10.62%
OCF(TTM)1.66
OCFY22.16%
SpS14.31
BVpS7.88
TBVpS-1.29
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.77% | ||
| ROE | -16.06% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.8% | ||
| FCFM | 5.54% |
ROA(3y)-115.95%
ROA(5y)-70.6%
ROE(3y)-222.82%
ROE(5y)-134.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.33%
GM growth 5Y1.2%
F-Score5
Asset Turnover0.88
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | 7.09 | ||
| Debt/EBITDA | 5.52 | ||
| Cap/Depr | 42.47% | ||
| Cap/Sales | 6.03% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 162.35% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.7 | ||
| Quick Ratio | 2.6 | ||
| Altman-Z | -6.49 |
F-Score5
WACC7.74%
ROIC/WACCN/A
Cap/Depr(3y)48.66%
Cap/Depr(5y)42.76%
Cap/Sales(3y)6.01%
Cap/Sales(5y)4.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.37%
EPS Next Y4.23%
EPS Next 2Y17.66%
EPS Next 3Y12.29%
EPS Next 5Y6.7%
Revenue 1Y (TTM)-2.37%
Revenue growth 3Y8.13%
Revenue growth 5Y35.95%
Sales Q2Q%-2.2%
Revenue Next Year-1.79%
Revenue Next 2Y-0.31%
Revenue Next 3Y0.41%
Revenue Next 5Y1.86%
EBIT growth 1Y9.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year141.27%
EBIT Next 3Y35.38%
EBIT Next 5Y20.45%
FCF growth 1Y25.37%
FCF growth 3Y9.25%
FCF growth 5Y54.93%
OCF growth 1Y2.46%
OCF growth 3Y14.82%
OCF growth 5Y57.92%
TELADOC HEALTH INC / TDOC FAQ
What is the ChartMill fundamental rating of TELADOC HEALTH INC (TDOC) stock?
ChartMill assigns a fundamental rating of 3 / 10 to TDOC.
What is the valuation status of TELADOC HEALTH INC (TDOC) stock?
ChartMill assigns a valuation rating of 3 / 10 to TELADOC HEALTH INC (TDOC). This can be considered as Overvalued.
Can you provide the profitability details for TELADOC HEALTH INC?
TELADOC HEALTH INC (TDOC) has a profitability rating of 3 / 10.
What is the expected EPS growth for TELADOC HEALTH INC (TDOC) stock?
The Earnings per Share (EPS) of TELADOC HEALTH INC (TDOC) is expected to grow by 4.23% in the next year.